Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash & Equivalents (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Cash & Equivalents for 16 consecutive years, with $63000.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 83.76% to $63000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63000.0 through Dec 2025, down 83.76% year-over-year, with the annual reading at $63000.0 for FY2025, 83.76% down from the prior year.
  • Cash & Equivalents hit $63000.0 in Q4 2025 for Guided Therapeutics, down from $87000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $2.7 million in Q3 2022 to a low of $63000.0 in Q4 2025.
  • Historically, Cash & Equivalents has averaged $790150.0 across 5 years, with a median of $566000.0 in 2021.
  • Biggest five-year swings in Cash & Equivalents: surged 5838.1% in 2021 and later plummeted 83.76% in 2025.
  • Year by year, Cash & Equivalents stood at $643000.0 in 2021, then skyrocketed by 259.72% to $2.3 million in 2022, then tumbled by 74.45% to $591000.0 in 2023, then crashed by 34.35% to $388000.0 in 2024, then tumbled by 83.76% to $63000.0 in 2025.
  • Business Quant data shows Cash & Equivalents for GTHP at $63000.0 in Q4 2025, $87000.0 in Q3 2025, and $185000.0 in Q2 2025.